Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Perjeta (pertuzumab) is a medication used for breast cancer treatment. Specifically designed to target HER2-positive breast cancer, Perjeta works synergistically with other anti-HER2 therapies to deliver enhanced efficacy in combating this aggressive form of cancer. Its mechanism of action involves blocking HER2 receptors, inhibiting cancer cell growth and proliferation. Approved by the FDA in 2012, Perjeta has since become a cornerstone in the treatment regimen for HER2-positive breast cancer, significantly improving patient outcomes and survival rates.
Before you buy Perjeta, it is crucial that you talk to your healthcare provider about potential side effects and cost of Perjeta.
| Fact Table | |
|---|---|
| Formula | C6470H10042N1726O2012S42 |
| License | FDA approved |
| Bioavailability | Not applicable (intravenous administration) |
| Legal status | Prescription Drug |
| Chemical Name | Pertuzumab |
| Elimination half-life | 18 days |
| Dosage (Strength) | 420 mg/14 mL |
| Pregnancy | Contraindicated; may cause fetal harm |
| Brands | Perjeta |
| Protein binding | Not applicable (antibody) |
| PubChem CID | 50928892 |
| MedlinePlus | a613040 |
| ChEBI | 77979 |
| ATC code | L01XC13 |
| DrugBank | DB06366 |
| KEGG | D10109 |
| Routes of administration | Intravenous |
Perjeta is administered intravenously by a qualified healthcare professional in a clinical setting. The dosage and administration schedule may vary depending on individual patient factors such as overall health, treatment history, and response to therapy. Typically, Perjeta 420 mg is combined with other anti-HER2 agents such as trastuzumab and chemotherapy drugs for maximum efficacy. Your healthcare provider will determine the appropriate dosage and treatment regimen tailored to your specific condition. It is crucial to adhere strictly to the prescribed treatment plan and attend all scheduled appointments for optimal therapeutic benefits.
The active ingredient in Perjeta is pertuzumab.
Before initiating treatment with Perjeta, it is essential to inform your healthcare provider about any pre-existing medical conditions, ongoing medications, allergies, or other relevant health information. Certain medical conditions or medications may interact with Perjeta or increase the risk of adverse effects.
Caution is warranted in patients with a history of heart conditions or impaired cardiac function, as Perjeta may exacerbate cardiac complications. Regular monitoring of cardiac function and overall health parameters is recommended throughout the course of Perjeta therapy to mitigate potential risks.
Perjeta may cause fetal harm if administered during pregnancy, and appropriate contraceptive measures should be implemented during treatment and for a specified duration thereafter.
Perjeta may interact with other medications or substances, potentially altering its efficacy or increasing the risk of adverse effects. It is imortant to disclose all medications, including prescription drugs, over-the-counter medications, vitamins, supplements, and herbal remedies, to your healthcare provider before starting Perjeta treatment. Certain medications, particularly those affecting cardiac function or liver metabolism, may interact with Perjeta and require dose adjustments or alternative treatment strategies. Additionally, herbal supplements or complementary therapies may interfere with Perjeta's mechanism of action or exacerbate side effects. Your healthcare provider can provide guidance on potential interactions and appropriate management strategies to ensure the safe and effective use of Perjeta.
Common side effects associated with Perjeta treatment include:
What is Perjeta?
Perjeta (pertuzumab) is a targeted cancer therapy used in combination with other medicines to treat HER2-positive breast cancer.
How does Perjeta work?
Perjeta works by blocking the HER2 receptors on the surface of breast cancer cells, preventing them from receiving growth signals.
Does Perjeta cause neuropathy?
Yes, peripheral neuropathy (numbness or tingling in hands or feet) is a reported side effect of Perjeta.
Is Perjeta chemotherapy?
No, Perjeta is not a chemotherapy drug. It is a targeted cancer therapy.
Why is Perjeta given before Herceptin?
Perjeta and Herceptin target different areas of the HER2 receptor, so they work in a complementary manner when used together.
Does Perjeta cause hair loss?
Yes, hair loss is a common side effect of Perjeta.
What are the side effects of Perjeta?
Common side effects of Perjeta include fatigue, nausea, vomiting, diarrhea, risk of infection, hair loss, and peripheral neuropathy.
How long do Perjeta side effects last?
Side effects of Perjeta can be temporary or permanent. They may go away during treatment as your body adjusts to the medicine.
How long do you take Perjeta?
Perjeta is usually taken every 3 weeks for 18 to 25 months. The exact duration depends on the individual’s response to treatment and the type of breast cancer.
